Microfluidic Application Centre Appoints Gillian Davis to Strategic Commercial Role
News Sep 17, 2007
Dolomite has appointed Dr Gillian Davis to the position of Commercial Director. In this strategic role, Gillian will be instrumental in securing new business opportunities and managing customer relations for Dolomite’s microfluidic capabilities and services.
‘This is an exciting development for us,’ said Mark Gilligan, Managing Director of Dolomite, ‘and reflects the increasing level of interest we are experiencing around the world from customers interested in working with us to bring their microfluidic concepts to market.’
‘I am delighted to welcome Gillian on board, she brings to the company not only a strong background in business development, but also extensive experience of working at the cutting edge of a diverse range of technical disciplines, including materials processing, liquid crystal displays and fibre optic communications. Having people on board with a broad technical background is particularly important to a company, such as Dolomite, which offers a service with an extremely wide application base, including environmental monitoring, clinical diagnostics, drug discovery, nuclear fuels reprocessing and forensic science.’
Dolomite’s key strength lies in being able to offer a complete service to customers from problem conceptualisation and feasibility testing through to full instrument design and development.
The Company says, Gillian’s appointment is just the beginning of Dolomite’s efforts to meet the demand from customers for a partner they can work with to bring their concepts for microfluidic products to market.
Precision NanoSystems to Host Nanomedicines SymposiumNews
Precision NanoSystems holds its second annual nanomedicines symposium called Nanomedicines that will discuss the latest developments in nanomedicine research.READ MORE
Miniature Technology, Big Hope for Disease DetectionNews
Researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) have described a new sequence of printing steps that are less damaging to bioreceptors than previous approaches.READ MORE